Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of rinatabart sesutecan monotherapy in advanced gastrointestinal cancers
NL-OMON61528Phase 2Not yet recruiting
- Sponsor
- Genmab
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rinatabart sesutecan in colorectal cancer (CRC), gastric cancer (GC), gastroesophageal junction adenocarcinoma and 4 more, sponsored by Genmab. Primary endpoint: Confirmed objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rinatabart sesutecan
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON61528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61528.